Get the Stockscreener App
0.6116
7.30%
0.0416
Tonix Pharmaceuticals Holding Corp stock is traded at $0.6116, with a volume of 278.90M.
It is up +7.30% in the last 24 hours and up +221.89% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$0.57
Open:
$0.5619
24h Volume:
278.90M
Relative Volume:
3.25
Market Cap:
$114.30M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-0.0327
EPS:
-18.6875
Net Cash Flow:
$-114.09M
1W Performance:
+154.30%
1M Performance:
+221.89%
6M Performance:
-54.70%
1Y Performance:
-94.96%
1-Day Range:
$0.5348
$0.6999
1-Week Range:
$0.2826
$1.30
52-Week Range:
$0.118
$14.08
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
0.6116 | 114.30M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals ups offering to $250 million - Investing.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 11.3%Time to Buy? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.7%Should You Sell? - MarketBeat
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application for Tnx-102 Sl for Fibromyalgia - Marketscreener.com
FDA accepts new fibromyalgia drug application from Tonix Pharma By Investing.com - Investing.com Australia
FDA Accepts NDA for Tonix’s Sleep-Improving Drug for Fibromyalgia - Sleep Review
TSX 60 Capped Index (TXCI) QuotePress Release - The Globe and Mail
TSX Composite Dividend Index (TXDC) QuotePress Release - The Globe and Mail
What's Going On With Tonix Pharmaceuticals Stock Today? - Benzinga
FDA accepts Tonix’s NDA for non-opioid fibromyalgia drug TNX-102 SL - Invezz
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Tonix Pharmaceuticals Gets FDA Review of Fibromyalgia Drug - Marketscreener.com
Tonix stock jumps on FDA review for pain drug (TNXP:NASDAQ) - Seeking Alpha
Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone - TipRanks
FDA accepts new fibromyalgia drug application from Tonix Pharma - Investing.com
Tonix Pharmaceuticals Announces FDA Acceptance of the New - GlobeNewswire
Tonix's Breakthrough Fibromyalgia Drug Takes Major Step Forward with FDA NDA Acceptance - StockTitan
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
Certain Options of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 11-DEC-2024. - Marketscreener.com
Certain Common Stock of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 11-DEC-2024. - Marketscreener.com
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers - BioSpace
Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on January 25, 2023. - Marketscreener.com
Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on September 6, 2024. - Marketscreener.com
Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires - GlobeNewswire
TNXP: NDA Filed for TNX-102 SL in Fibromyalgia… - Yahoo Finance
Tonix Pharmaceuticals Holding (STU:TPM0) Operating Income : €-74.27 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) EBITDA per Share : €-24.48 (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) FCF Yield % : -195.15 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) EV-to-Revenue : 1.46 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) Capex-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) PS Ratio : 27.04 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Inventories, Inven - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Long-Term Debt : €4.66 Mil (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Retained Earnings : €-638.44 Mil (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Earnings Yield % : N/A% (As of Nov. 30, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Shares Outstanding (EO - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) 5-Year Yield-on-Cost % : 0.00 (As of Nov. 28, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Cash Flow from Operati - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Earnings Power Value (EPV) : $-3.87 (As of Sep24) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Free Cash Flow per Sha - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Cash, Cash Equivalents, Marketable Securities : $28.23 Mil (As of Sep. 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Future 3-5Y Total Reve - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Debt-to-Revenue : 0.77 (As of Sep. 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Operating Margin % : -492.06% (As of Sep. 2024) - GuruFocus.com
Tonix Pharma talks NDA for Fibromyalgia drug, FDA decision on NDA acceptance expected December 2024 - Proactive Investors USA
Tonix Pharmaceuticals Holding (FRA:TPM0) Effect of Exchange Rate Changes : €-0.03 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference - The Manila Times
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):